Detail akcie Citius Pharmactc Rg online

Business Summary: Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
Financial Summary: BRIEF: For the fiscal year ended 30 September 2025, Citius Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders decreased 7% to $37.4M. Lower net loss reflects Critical care and cancer care segment loss decrease of 8% to $38.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$5.97 to -$3.38.